DataJoint offers an open-source–based SaaS platform that structures, processes, and analyzes complex multimodal data for researchers in neuroscience, oncology, and systems biology. The system automates data pipelines and reproducibility, enabling advanced AI/ML workflows across academic and commercial labs. More than 100 laboratories at institutions such as Johns Hopkins, UCSF, Harvard, and UCL already rely on the software. With fresh capital, the company plans to scale operations, deepen product capabilities, and extend its reach into U.S. and European pharmaceutical and life-science enterprises. Road-mapped enhancements include achieving SOC2, HIPAA, and ISO27001 compliance to meet enterprise security standards. DataJoint’s geographic footprint spans Barcelona, Salt Lake City, and Austin, reflecting its international ambitions. The firm’s customer traction and recent accelerator selection by PharmStars underscore growing commercial interest. This $4.9 million seed round provides the financial runway for these expansion and product initiatives.

Total raised

$9M

Funding rounds

2

Latest round

Seed

Latest activity

Sep 2025